Top Companies Developing Subcutaneous Biologics Formulation Technology
.png)
Published: December 2024
In order to enhance the patient compliance and deliver efficacious, target biologics, the pharmaceutical industry has observed the reliance on advanced formulation technology platforms that offer better bioavailability for higher drug concentration. We analyzed over 150 companies offering approved / clinical-stage subcutaneous biologics, subcutaneous formulation technologies. In this article, discover 7 top technology developers and their capabilities in this industry
Over the years, the incidence and prevalence of chronic diseases, such as diabetes, multiple sclerosis and rheumatoid arthritis, have increased significantly. Presently, the recommended treatment options for such clinical conditions are mostly biologics, which need to be administered via parenteral routes in order to ensure maximum therapeutic benefit. Given the inherent requirement for frequent medication, patients suffering from such long-lasting clinical conditions generally end up spending high amounts on not only the prescribed therapeutic regimen, but also on numerous hospital visits for dose administration. However, several drug delivery devices (such as autoinjectors, needle free drug delivery devices, prefilled syringes) that enable patients to self-administer their respective medications are now available.
Over time, the growing adoption of such devices has a significant impact on patients suffering from chronic illnesses. This is primarily because of their ease-of-use and cost effectiveness, in terms of allowing consumers to avoid expensive visits to hospitals / outpatient clinics. Moreover, such solutions have been shown to have a profound impact on patient compliance and therapy adherence.
Given the rising demand for such drugs / therapies, the need for advanced formulation / drug delivery technologies capable of efficiently aiding the development of subcutaneously deliverable therapy products, has also become more pronounced. As a result, many companies are engaged in developing formulation platforms in order to make injectable biopharmaceutical products that can be packaged in an autoinjector or pen-injector or other similar devices, which can be conveniently used by patients and / or caregivers. Further, it is worth highlighting that many pharmaceutical / biopharmaceutical products, which were initially developed for delivery via other modes of administration, are now being reformulated for delivery via the subcutaneous route.
Roots Analysis has conducted an exhaustive study on Subcutaneous Biologics Market featuring the current market landscape and future opportunity for the companies developing subcutaneous formulation technologies, over a span of 11 years.
Table of Contents
Below, we have listed (in alphabetical order), the top 7 companies developing subcutaneous biologics formulation technology.
- Adocia
- Alteogen
- Ascendis Pharma
- Creative Biolabs
- Creative Biomart
- Pacira BioSciences
- Xeris Biopharma
Interested in exploring all 40+ companies engaged in the development of subcutaneous biologics formulation technologies?
Discover Below the Details on 7 Top Companies Developing Subcutaneous Biologics Formulation Technology
Let us deep dive to understand the activity of the 7 companies (shortlisted on the basis of company size (companies having 51-1,000 employees), and year of establishment (2005-2008)) engaged in the development of subcutaneous biologics formulation technology. It is essential to note that the selection of top players can differ substantially according to the defined criteria.
With a Strong Intellectual Portfolio, Adocia Continues to Develop Innovative Therapies for Diabetes and Obesity
1. Adocia
Adocia is a French biotechnology company dedicated to the development of innovative formulations of already approved therapeutic products. The company primarily focuses on the development of injectable products for the treatment of various chronic metabolic diseases (particularly diabetes). The company utilizes its proprietary platform technology, BioChaperone®, that not only protects innovative polymers, oligomers and small organic compounds from enzymatic degradation but also improves their therapeutic performance, thereby making them easy to use for patients.
Adocia: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2005 |
| Number of Employees | 51-200 |
| Headquarter |  |
Adocia: Technology Portfolio
| Parameters | BioChaperone Technology |
| Fundamental Principle |
|
| Type of Molecule |
|
| Route of Administration |
|
| Therapeutic Area |
|
| Key Characteristics |
|
Recent Initiatives by Adocia: In October 2024, the company announced the patent filing of stable formulation of GLP-1 (semaglutide) and amylin analogs (cagrilintide), based on BioChaperone technology, that will support the treatment of obesity and diabetes.
Further details on recent initiatives taken by Adocia as well as other companies engaged in the development of subcutaneous biologics formulation technology have been provided in detail in the report.
With a Strong Research Workforce and Platforms, Alteogen is Engaged in Reformulation of Parenteral Drugs into Subcutaneous Route
2. Alteogen
Alteogen is South Korea-based biopharmaceutical company, that is focused on the development and commercialization of the drugs belonging to three major drug classes (ADC, complex antibody biosimilars and long-acting biobetters), by using its proprietary technologies. Alteogen's cutting-edge focus areas include long acting biobetters, proprietary ADCs, Hybrozyme™ technology, and monoclonal antibody biosimilars. The company collaborates with overseas partners to advance its innovative pipeline and remains committed to developing transformative biopharmaceutical solutions.
Alteogen: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2008 |
| Number of Employees | 51-200 |
| Headquarter |  |
Alteogen: Technology Portfolio
| Parameters | Hybrozyme ALT-B4 |
| Fundamental Principle |
|
| Type of Molecule |
|
| Route of Administration |
|
| Key Characteristics |
|
Recent Initiatives by Alteogen: In November 2024, the company announced a strategic collaboration with Daiichi Sankyo, in order to license ALT-B4 for the development and commercialization of subcutaneous ENHERTU® (a HER2 directed antibody drug conjugate).
Further details on recent initiatives taken by Alteogen as well as other companies engaged in the development of subcutaneous biologics formulation technology have been provided in detail in the report.
Ascendis Pharma Aims to Make Global Impact through Commercialization of YORVIPATH for Hypoparathyroidism
3. Ascendis Pharma
Ascendis Pharma is a Denmark-based biotechnology company that specializes in developing innovative formulations of existing drugs with predictable and sustained-release characteristics. The company is engaged in the development of novel therapeutics for various therapeutic areas, including endocrinological disorders, rare disorders, oncological disorders, metabolic disorders and ophthalmological disorders. In December 2007, Ascendis Pharma acquired the rights of TransCon™ technology (through the acquisition of Complex Biosystems) in order to enhance its drug development capabilities and enable the advancement of its therapeutic pipeline.
Ascendis Pharma: Company Details
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2007 |
| Number of Employees | 501-1,000 |
| Headquarter |  |
Ascendis Pharma: Technology Portfolio
| Parameters | TransCon™ Technology |
| Fundamental Principle |
|
| Type of Molecule |
|
| Route of Administration |
|
| Therapeutic Area |
|
| Key Characteristics |
|
Recent Initiatives by Ascendis Pharma: In November 2024, the company entered into a strategic collaboration with Novo Nordisk, in order to grant the rights of TransCon platform for the development, manufacturing and commercialization of products for the treatment of metabolic and cardiovascular disorders.
Further details on recent initiatives taken by Ascendis Pharma as well as other companies engaged in the development of subcutaneous biologics formulation technology have been provided in detail in the report.
Through Wide Range of Custom Services in Antibody Discovery and Engineering, Creative Biolabs is Dedicated towards Offering Valuable Solutions
4. Creative Biolabs
Creative Biolabs is a US-based company engaged in the manufacturing of biotechnology products, ranging from early drug discovery to development. Additionally, the company offers customized services tailored to meet the diverse needs of its global clientele, thereby providing services related to recombinant discovery, targeted immunotherapy, and antibody drug conjugate (ADC) development. It is also worth mentioning that the firm specializes in developing innovative technologies and products for subcutaneous drug administration through its expertise in liposome formulation and delivery systems.
Creative Biolabs: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2005 |
| Number of Employees | 51-200 |
| Headquarter |  |
Creative Biolabs: Technology Portfolio
| Parameters | Long-Acting Injectable (LAI) Technology |
| Fundamental Principle |
|
| Type of Molecule |
|
| Route of Administration |
|
| Therapeutic Area |
|
| Key Characteristics |
|
Recent Initiatives by Creative Biolabs: In November 2024, the company participated in 37th edition of the European Macrophage and Dendritic cell Biology (EMDS) meeting, which was held in Vienna, Austria in order to gain visibility in the pharmaceutical domain.
Further details on recent initiatives taken by Creative Biolabs as well as other companies engaged in the development of subcutaneous biologics formulation technology have been provided in detail in the report.
Creative BioMart Offers a Variety of Products and Solutions to Support Research, Development and Production of Biologic Drugs
5. Creative BioMart
Creative BioMart is a US-based firm specializing in the manufacturing of high-quality protein products, including recombinant proteins, native proteins, GMP proteins, therapeutic proteins and diagnostic enzymes for research organizations and industry players. The company claims to offer more than 100,000 recombinant proteins, peptides and antibodies (including more than 5,000 recombinant protein products). Moreover, the firm provides high-quality protein analytical services, including custom protein services, protein analysis, discovery and translational services, intended to support the research, manufacturing, and clinical development of both native and recombinant proteins.
Creative BioMart: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2005 |
| Number of Employees | 51-200 |
| Headquarter |  |
Creative BioMart: Technology Portfolio
| Parameters | High Concentration Formulation (HCF) Technology |
| Fundamental Principle |
|
| Type of Molecule |
|
| Route of Administration |
|
| Key Characteristics |
|
Recent Initiatives by Creative BioMart: In September 2024, the company showcased its portfolio in the NIH Research Festival Biotech Vendor Exhibits 2024, which was held in Maryland, US.
Further details on recent initiatives taken by Creative BioMart as well as other companies offering subcutaneous biologics formulation technology have been provided in detail in the report.
Pacira BioSciences is Extensively Engaged in the Development of Non-Opioid Pain Relief Drugs
6. Pacira BioSciences
Pacira BioSciences claims to be a leading provider of non-opioid solutions for pain management and regenerative health, focused on delivering innovative therapies designed to reduce or eliminate the reliance on opioids for pain relief. Further, the company has developed EXPAREL®, a long-acting local analgesic administered via subcutaneous route for postsurgical pain management. It is interesting to note that the firm’s product portfolio focuses on opioid minimization, sustained pain control, and enhanced recovery, aiming to meet unmet medical needs and improve clinical outcomes.
Pacira BioSciences: Company OverviewKey Parame
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2006 |
| Number of Employees | 501-1,000 |
| Headquarter |  |
Pacira BioSciences: Technology Portfolio
| Parameters | Multivesicular Liposome Technology |
| Fundamental Principle |
|
| Type of Molecule |
|
| Route of Administration |
|
| Therapeutic Area |
|
| Key Characteristics |
|
Recent Initiatives by Pacira BioSciences: In November 2024, the company announced the safety and efficacy data of PCRX-201, a sustained-release gene therapy, which is administer locally for the treatment of osteoarthritis.
Further details on recent initiatives taken by Pacira BioSciences as well as other companies engaged in the development of subcutaneous biologics formulation technology have been provided in detail in the report.
Xeris Biopharma Aims to Develop Novel Drug Products across Various Therapeutic Areas, through Strategic Collaborations
7. Xeris Biopharma
Xeris Biopharma is a US-based biopharmaceutical company focused on the development and commercialization of innovation formulations of ready-to-use and patient-friendly injectable drugs. The company claims to develop a range of products targeting various disease indications, including diabetes, epilepsy, and immune system disorders. It has developed two proprietary formulation technology platforms, namely XeriJect® and XeriSol®, which have been designed to facilitate subcutaneous, intradermal and intramuscular administration of highly concentrated, ready-to-inject formulations for both small and large molecule drugs (proteins, peptides, and antibody-based therapeutics). According to the firm’s website, these formulations can be administered using various devices, such as syringes, autoinjectors, multi-dose pens and infusion pumps. Apart from its principal office located in Chicago, the company also has a product development site in San Diego.
Xeris Biopharma: Company Overview
| Key Parameters | Description |
| Company Logo |  |
| Year of Establisment | 2005 |
| Number of Employees | 201-500 |
| Headquarter |  |
Xeris Biopharma: Technology Portfolio
| Parameters | XeriJect® Technology | XeriSol® Technology |
| Fundamental Principle |
|
|
| Type of Molecule |
|
|
| Route of Administration |
|
|
| Therapeutic Area |
|
|
| Key Characteristics |
|
|
Recent Initiatives by Xeris Biopharma: In May 2024, the company announced the Phase II results of XP-1821, a once-weekly subcutaneous small molecule (based on XeriSol technology) for the treatment of hypothyroidism.
details on recent initiatives taken by Xeris Biopharma as well as other companies engaged in the development of subcutaneous biologics formulation technology have been provided in detail in the report.
What About the Other Companies Developing Subcutaneous Biologics Formulation Technology?
The above presentation features seven top companies (technology developers) selected from a pool of over 150 players (drug and technology developers) that we have compiled. If you're interested, you can download the Sample Report on this topic by Roots Analysis. For personalized assistance in identifying the most relevant solutions based on your specific criteria, please don't hesitate to reach out to us at sales@rootsanalysis.com.
Source
- https://www.adocia.com/composants/uploads/2024/10/ADOCIA-PR-BioChaperone-Amylin-GLP1-Combinations.pdf
- http://www.alteogen.com/en/ir_1/?uid=2418&mod=document
- https://investors.ascendispharma.com/news-releases/news-release-details/ascendis-pharma-and-novo-nordisk-sign-collaboration-development
- https://events.creative-biolabs.com/emds-2024
- https://investor.pacira.com/news-releases/news-release-details/pacira-announces-104-week-safety-and-efficacy-data-following
- https://xerispharma.gcs-web.com/news-releases/news-release-details/xeris-biopharma-announces-positive-topline-phase-2-clinical-data